BioMedNewsBreaks — Adageis’ Platform Tackles Healthcare Complexities with AI

Adageis was featured in a recent article that discussed its powerful and patented AI-centric software solution. “Healthcare is a complicated place, and navigating the system is extremely difficult for patients,” Adageis’ CEO Shane Speirs was quoted as saying. “What Adageis does is provide a simple solution to healthcare organizations, ranging from large, multi-state, multi-specialty healthcare groups to independent practices across the country. We offer a solution that meets everyone’s needs, helping providers and organizations drive revenue by delivering high-quality care, which everyone can align with.”

To view the full article, visit https://ibn.fm/i5Oo0

About Adageis

Adageis is a healthcare technology innovator focused on addressing inefficiencies in care delivery through AI and machine learning. Its solutions empower healthcare providers and healthcare organizations to enhance patient outcomes, streamline operations, and drive increased revenue through meeting the demands of value-based care. By integrating advanced technologies with minimal disruption, Adageis remains a leader in driving meaningful change across the healthcare sector. For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Lead Program in Virtual CEO Segment 

  CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on treating primary and metastatic cancers…

8 hours ago

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Multiple 2025–2026 Catalysts Across Rare Disease Pipeline

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical…

10 hours ago

BioMedNewsBreaks — Why HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

HeartBeam (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and…

1 day ago

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in Editorial Highlighting Breakthrough Genetic Medicine Platform 

Calidi Biotherapeutics (NYSE American: CLDI) announced its feature in a NetworkNewsWire editorial discussing the company’s…

1 day ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Declares 25% Preferred Stock Dividend Linked to AVERSA Fentanyl Approval 

Nutriband (NASDAQ: NTRB) announced that its Board of Directors has approved a 25% preferred stock…

1 week ago

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Added to Four Russell Indexes in 2025 Reconstitution

Nutriband (NASDAQ: NTRB) has been added to the Russell Microcap, Russell Microcap Growth, Russell 3000E,…

1 week ago